| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 12/28/2006 | CA2611151A1 Use of sanglifehrin in hcv |
| 12/28/2006 | CA2610416A1 Tubulin inhibitor and process for its preparation |
| 12/28/2006 | CA2610326A1 Substituted pyrr0lidin-2-0nes , piperidin-2-0nes and isothiazolidine-1, 1-dioxides, their use as kv1.5 potassium channel blockers and pharmaceutical preparations comprising them |
| 12/28/2006 | CA2610281A1 Therapeutic agent for cancer |
| 12/28/2006 | CA2610075A1 Substituted heterocycles, their use as medicament, and pharmaceutical preparations comprising them |
| 12/28/2006 | CA2608929A1 Imidazolinone and hydantoine derivatives as novel inhibitors of histone deacetylase |
| 12/28/2006 | CA2603141A1 Treatment of autoimmune disorders with a neurotoxin |
| 12/28/2006 | CA2598216A1 Androgen receptor modulator compounds and methods |
| 12/28/2006 | CA2587189A1 Methods and compositions involving mirna and mirna inhibitor molecules |
| 12/27/2006 | EP1736775A1 Novel ligand of g protein coupled receptor protein and use thereof |
| 12/27/2006 | EP1736547A1 Guanylate binding protein (GBP-1) as inhibitor of cell proliferation |
| 12/27/2006 | EP1736541A1 Novel galectin 9 modification protein and use thereof |
| 12/27/2006 | EP1736484A1 An gene enginf; ering recombinant anti-cea, anti-cd3 and anti-cd28 single-chain tri-specific antibody |
| 12/27/2006 | EP1736472A1 2-aminopyridine derivative |
| 12/27/2006 | EP1736470A2 Pyrimidine derivatives as CB2 cannabinoid receptor modulators |
| 12/27/2006 | EP1736206A1 Physiologically active composition and process for producing the same |
| 12/27/2006 | EP1736169A1 Anticancer activity enhancer of viral therapy and method of cancer prevention or treatment |
| 12/27/2006 | EP1736163A1 CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies |
| 12/27/2006 | EP1736154A1 Use of PP-1 inhibitors to prevent missplicing events |
| 12/27/2006 | EP1736152A2 Physiologically stable compositions of butyric acid as well as butyric acid salts and derivatives for treating wounds |
| 12/27/2006 | EP1735432A1 Cancerous disease modifying antibodies |
| 12/27/2006 | EP1735348A1 Human anti-epidermal growth factor receptor antibody |
| 12/27/2006 | EP1735311A1 Beta-carbolines useful for treating inflammatory disease |
| 12/27/2006 | EP1735281A2 Synthesis of indenoisoquinoliniums and methods of use |
| 12/27/2006 | EP1735277A1 2-alkylidene-18,19-dinor-vitamin d compounds |
| 12/27/2006 | EP1735274A1 Nonpeptide inhibitors of matrix metalloproteinases |
| 12/27/2006 | EP1735271A2 Compounds for modulating the glycolysis enzyme complex and/or the transaminase complex |
| 12/27/2006 | EP1735013A2 Alpha-emitting hydroxyapatite particles |
| 12/27/2006 | EP1735002A2 Cancer therapy comprising a nuclear receptor ligand and a hdac inhibitor |
| 12/27/2006 | EP1734995A1 Monoclonal antibodies to hepatocyte growth factor |
| 12/27/2006 | EP1734985A2 Methods for suppressing neovascularization using ephrinb2 |
| 12/27/2006 | EP1734972A2 Method of treating solid tumors and leukemias using combination therapy of vitamin d and anti-metabolic nucleoside analogs |
| 12/27/2006 | EP1734951A2 Diphenyl-indol-2-on compounds and their use in the treatment of cancer |
| 12/27/2006 | EP1734944A1 4-oxo-fenretinide, administered alone and in combination with fenretinide, as preventive and therapeutic agent for cancer |
| 12/27/2006 | EP1734918A1 Pharmaceutical composition for treating hair loss and benign prostatic hyperplasia |
| 12/27/2006 | EP1651652B1 Substituted tetrahydrobenzothienopyrimidinamine compounds useful for treating hyper-proliferative disorders |
| 12/27/2006 | EP1549329B1 Extract with anti-tumor and anti-poisonous activity |
| 12/27/2006 | EP1480961B1 Glutaminyl based dpiv inhibitors |
| 12/27/2006 | EP1443925B1 Naphthyridine derivatives, their preparation and their use as phosphodiesterase isoenzyme 4 (pde4) inhibitors |
| 12/27/2006 | EP1430051B1 N-(4-(4-methylthiazol-5-yl)pyrimidin-2-yl)-n-phenylamines as antiproliferative compounds |
| 12/27/2006 | EP1406876B1 2-anilino-pyrimidine derivatives as cyclin dependent kinase inhibitors |
| 12/27/2006 | EP1392276B1 Potentiation of therapeutic effects of polyunsaturated fatty acids |
| 12/27/2006 | EP1368317B1 Tryptase inhibitors |
| 12/27/2006 | EP1354047B1 Methods for screening compounds that modulate lipid metabolism |
| 12/27/2006 | EP1332372B1 Net, a transcription factor of the tcf family, as regulator of angiogenic factor expression |
| 12/27/2006 | EP1313695B1 Esters of 5-aminolevulinic acid as photosensitizing agents in photochemotherapy |
| 12/27/2006 | EP1284717B1 Formulation based on heparin, glycosaminoglycan or heparinoid, use of the formulation and the formulation base |
| 12/27/2006 | EP1242401B1 Cytotoxic agents comprising taxanes and their therapeutic use |
| 12/27/2006 | EP1222924B1 Anticancer agents |
| 12/27/2006 | EP1187826B1 Heterocyclic derivatives useful as anticancer agents |
| 12/27/2006 | EP1185618B1 A bacterial strain, processed plant extracts and probiotic compositions for human and veterinary use |
| 12/27/2006 | EP1073739B1 Cd40-interacting and traf-interacting proteins |
| 12/27/2006 | EP0973804B1 Anti-vegf antibodies |
| 12/27/2006 | CN1886506A Protein expressed in nk cell |
| 12/27/2006 | CN1886426A Antibodies that bind interleukin-4 receptor |
| 12/27/2006 | CN1886423A Glycoisoforms of adiponectin and uses thereof |
| 12/27/2006 | CN1886403A Use of a compound of formula (i) as an inhibitor of aromatase for therapeutic purposes and compounds of formula (1) thereas |
| 12/27/2006 | CN1886399A 喹唑啉衍生物 Quinazoline derivatives |
| 12/27/2006 | CN1886384A Quinazolinone compounds as anticancer agents |
| 12/27/2006 | CN1886378A 1,4-disubstituted isoquinilone derivatives as RAF-kinase inhibitors useful for the treatment of proliferative diseases |
| 12/27/2006 | CN1886353A Methods of [11C]-radiolabelling phenothiazine and phenothiazine-like compounds |
| 12/27/2006 | CN1886154A Clostridium botulinum C3 exotransferase compositions and methods for treating tumour spreading |
| 12/27/2006 | CN1886143A Agent and method for treating cancer comprising strontium, amino acid(s) and mineral agent(s) |
| 12/27/2006 | CN1886130A Use of 2-thia-dibenzo[e, h]azulenes for the manufacture of pharmaceutical formulations for the treatment and prevention of central nervous system diseases and disorders |
| 12/27/2006 | CN1886118A Solid forms of anti-EGFR-antibodies. |
| 12/27/2006 | CN1884554A Eucaryotic expression vector for treating tumour transfer and its construct method |
| 12/27/2006 | CN1884543A Recombinant phycoerythrin and its preparation method and application |
| 12/27/2006 | CN1884535A Anti human CD19 mouse immune globulin variable zone gene and uses |
| 12/27/2006 | CN1884530A Human XIAP target gene siRNA expression template |
| 12/27/2006 | CN1884505A Tumour related protein kinase RX17 and its uses |
| 12/27/2006 | CN1884301A Targeted function superantigen and its preparation method and use |
| 12/27/2006 | CN1884300A Targeted function anti-liver cancer superantigen and its preparation method and use |
| 12/27/2006 | CN1884295A Oxygen deficient induction factor1 antisense oligonucleotide and its uses |
| 12/27/2006 | CN1884293A Anthraquinone glycoside compound with anti ovary tumour effect |
| 12/27/2006 | CN1884273A Naphtho dihydrofuryl o-quinone compound and its preparation method and use |
| 12/27/2006 | CN1884266A Aromatic-cyclo and heterocyclo acylmethyl imidazole salts compound and method for preparing same |
| 12/27/2006 | CN1884261A Hydantion method compolete preparation of chromium selenomethionine compounds (III) and its uses |
| 12/27/2006 | CN1883710A Chemical modification method of antineoplastic oligopeptide and application thereof |
| 12/27/2006 | CN1883709A Bi-functional targeting antineoplastic polypeptide and application thereof |
| 12/27/2006 | CN1883703A Serine protease inhibitor of Rana grahami, its gene and application |
| 12/27/2006 | CN1883686A Medicine for treating liver cancer |
| 12/27/2006 | CN1883679A Medicine for treating pulmonary tuberculosis |
| 12/27/2006 | CN1883659A Chinese medicine for treating skin lesion and malignant tumor and application thereof |
| 12/27/2006 | CN1883648A Medicine for treating leukemia |
| 12/27/2006 | CN1883640A Medicine for treating leucocytopenia caused after tumor radiotherapy and chemotherapy |
| 12/27/2006 | CN1883631A Medicine for treating lung cancer |
| 12/27/2006 | CN1883619A Pharmaceutical composition of viola yedoensis and method for preparing same |
| 12/27/2006 | CN1883589A Cancer-treating medicine using white ant as main raw material |
| 12/27/2006 | CN1883582A Pharmaceutical composition for treating liver disease and method for preparing same |
| 12/27/2006 | CN1883567A Chinese medicinal preparation for treating lung cancer and medicinal ointment thereof |
| 12/27/2006 | CN1883556A A nano preparation of 'Kang'ai' injection and method for preparing same |
| 12/27/2006 | CN1883545A A compound nano injection preparation of flavescent sophora root and preparation method thereof |
| 12/27/2006 | CN1883540A A lyophilized injection of pharmaceutical composition and method for preparing same |
| 12/27/2006 | CN1883538A A nano Aidi injection preparation and method for preparing same |
| 12/27/2006 | CN1883522A An anti-tumor antibiotic and anti-inflammation pharmaceutical composition and preparation method thereof |
| 12/27/2006 | CN1883497A Ginsenoside Rh2 hydroxypropyl-beta-cyclodextrin inclusion compound and preparation method thereof |
| 12/27/2006 | CN1883492A Water solution of 20(R)-ginsenoside Rg3 pharmaceutical composition and preparation method thereof |
| 12/27/2006 | CN1883490A Application of sucrose ester compound in preparation of anti-tumor medicine |
| 12/27/2006 | CN1883471A A nano sodium cantharidin injection and preparation method thereof |
| 12/27/2006 | CN1883467A Orally administered anti-tumor medicinal composition of taxane and administration method thereof |